Mr. Stefano Picone reports

CONAVI MEDICAL ANNOUNCES GRANT OF STOCK OPTIONS

Conavi Medical Corp.'s board of directors has approved grants of stock options pursuant to the terms of the omnibus equity incentive plan effective Jan. 2, 2025. A total of 1,073,685 stock options have been awarded to directors, officers, employees and consultants of the company. The stock options are exercisable at a price of 70 cents per share (being the closing price of the company's shares on the TSX Venture Exchange on Jan. 2, 2025) for a period of 10 years from the date of the grant.

Of such 1,073,685 stock options, the company's independent directors -- Robert Mitchell, Susan Allen and Aaron Davidson -- were respectively granted 78,877, 51,442 and 102,882 stock options, and the company's officers -- Thomas Looby, Stefano Picone, Amandeep Thind, Robert Skidmore and Travis More -- were respectively granted 514,402, 74,763, 74,761, 43,211 and 21,606 stock options. The remaining stock options were granted to other employees and consultants.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the United States Food and Drug Administration, and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.